NYSE : CRL
Charles River Laboratories International, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 359.41 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 17.16B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 17.16B |
| Enterprise Value | 20.00B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 47.74M |
| Shares Outstanding | 47.74M |
| Shares Change (YoY) | -3.44% |
| Shares Change (QoQ) | -1.90% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 121.37% |
| Float | 47.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 29.15 |
| PS Ratio | 4.29 |
| Forward PS | 4.39 |
| PB Ratio | 6.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 46.30 |
| P/OCF Ratio | 29.47 |
| PEG Ratio | 2.50 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.00 |
| EV / EBITDA | 23.55 |
| EV / EBIT | 40.34 |
| EV / FCF | 53.97 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.35 |
| Quick Ratio | 0.80 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | 3.15 |
| Debt / FCF | 8.19 |
| Interest Coverage | 4.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -7.52% |
| Return on Assets (ROA) | 4.11% |
| Return on Invested Capital (ROIC) | 8.56% |
| Return on Capital Employed (ROCE) | 7.75% |
| Weighted Average Cost of Capital (WACC) | 10.28% |
| Revenue Per Employee | $202,994 |
| Profits Per Employee | -$12,104 |
| Employee Count | 19,700 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 8.36 |
Taxes
| Measure | Value |
|---|
| Income Tax | 52.63M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +99.51% |
| 50-Day Moving Average | 301.91 |
| 200-Day Moving Average | 221.78 |
| Relative Strength Index (RSI) | 68.05 |
| Average Volume (20 Days) | 1,203,384 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.83M |
| Short Previous Month | 2.23M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 6.00% |
| Short Ratio (days to cover) | 2.77 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.00B |
| Gross Profit | 1.38B |
| Operating Income | 495.84M |
| Pretax Income | -183.67M |
| Net Income | -238.46M |
| EBITDA | 849.12M |
| EBIT | 495.84M |
| Loss Per Share | -$4.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 192.03M |
| Total Debt | 3.03B |
| Net Cash | -2.84B |
| Net Cash Per Share | -$59.54 |
| Equity (Book Value) | 2.89B |
| Book Value Per Share | 59.50 |
| Working Capital | 394.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 582.15M |
| Capital Expenditures | -211.54M |
| Depreciation & Amortization | 353.28M |
| Net Borrowing | 321.89M |
| Free Cash Flow | 370.61M |
| FCF Per Share | $7.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | 34.59% |
| Operating Margin | 12.40% |
| Pretax Margin | -4.59% |
| Profit Margin | -5.96% |
| EBITDA Margin | 21.23% |
| EBIT Margin | 12.40% |
| FCF Margin | 9.27% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.44% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.36% |
| FCF Yield | 2.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $318.87 |
| Price Target Difference | -11.28% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 1.92% |
| EPS Growth Forecast (3Y) | 11.76% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.18 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |